Op-Ed from Dr. Jenny Hoffmann: 4 Times Is Not a Coincidence

The fourth time should address any question.

When a New England Medical Innovation Center portfolio company wins the Rhode Island Business Competition once, it’s a success. Twice, it’s momentum. Three times, it’s creditbilty. Four years in a row? That’s not coincidence—that’s a system working exactly as intended.

In a space as uncertain and high-risk as life sciences, repeatable success is rare; breakthrough ideas are everywhere, but what’s scarce is the ability to consistently turn those ideas into companies that are credible, fundable, and built to improve human health.

At NEMIC, that’s our mission: improving human health through innovation. And that mission only succeeds when innovation is grounded in practicality from the very beginning.

Too often, healthcare innovation starts with the assumption that a great idea will naturally find its way to patients. It won’t. The companies that succeed start somewhere more grounded—with a compelling, commercially viable opportunity.

That means asking hard questions early:
Who is going to pay for this product?
Why will they choose it over existing alternatives?
What evidence will they need to say yes?

These aren’t downstream questions. They are foundational. And when they are answered early, they shape everything that follows.  This is where an innovation process becomes critical.  Process is what turns insight into action. It creates discipline around defining milestones, aligning clinical and regulatory strategy, and building toward value inflection points that matter—not just scientifically, but commercially. Without that structure, even the most promising ideas stall. With it, they gain traction.

But building the company is only part of the challenge. The other part is telling the story.

Life science companies are capital-intensive. They require significant investment long before revenue. That means success depends not just on the strength of the science, but on the ability to communicate a clear, compelling, and credible path forward. A story that resonates with investors is not about hype.  It’s about coherence. It connects the unmet need, the solution, the evidence plan, and the market opportunity into something that investors can understand and believe in.

And no founder does this alone.

Growing a life science company requires surrounding entrepreneurs with the right expertise; from regulatory and clinical strategy to reimbursement, commercialization, and financing. These perspectives don’t just support the founder; they shape better decisions, earlier, when it matters most. This is what a repeatable model looks like. It’s not about picking winners, it’s about building them with intention.

Four consecutive wins at the Rhode Island Business Competition are not just a milestone for NEMIC portfolio companies. They are a signal that a disciplined, commercially grounded, and mission-driven approach to innovation works.

If we are serious about improving human health, we have to be equally serious about how we build and support the companies that deliver it.

Because innovation, on its own, is not enough.
It’s the process—and the purpose behind it—that turns ideas into impact.